Product Reports Resources Pricing Login Book a demo

Limbix

Biotech & Life Sciences · Palo Alto, United States · Founded 2016

Prescription digital therapeutics for adolescent mental health MoreLess

Founded in 2016 by Ben Lewis and Jon Sockell, Limbix operates at the intersection of technology and adolescent mental health. Lewis, with a background as an Engineering Manager at Facebook and founder of two other companies, and Sockell, a former Director of Marketing, established the company to address the critical need for accessible mental health treatments for young people. The company initially explored virtual reality for exposure therapy but pivoted in late 2019 to focus on mobile-based digital therapeutics. After raising a total of $31 million over several funding rounds, with notable contributions from investors like GSR Ventures and Sequoia Capital, Limbix was acquired by Big Health in July 2023.

Limbix develops prescription digital therapeutics (PDTs), which are software-based interventions prescribed by healthcare professionals to treat medical conditions. The company's business model targets health systems and payors, aiming to integrate its products into the existing healthcare framework as a new, evidence-based treatment option. This approach allows clinicians to prescribe the digital tools as an adjunct to traditional therapy for adolescents aged 13 to 22.

The company's flagship product is SparkRx, a smartphone application designed to help manage symptoms of adolescent depression. SparkRx is a multi-week, self-guided program based on the principles of Cognitive Behavioral Therapy (CBT), with a specific focus on behavioral activation. It uses features like mood tracking, problem-solving exercises, mindfulness activities, and a supportive chatbot named 'Limbot' to teach users coping skills and the relationship between their mood and actions. Clinical studies have shown that SparkRx can lead to a statistically significant reduction in depression symptoms. The product was launched under an FDA enforcement policy related to the COVID-19 pandemic, which permitted marketing without full FDA clearance to improve access to psychiatric digital health devices.

Keywords: prescription digital therapeutics, adolescent mental health, cognitive behavioral therapy, behavioral activation, mobile health, digital mental health, SparkRx, teen depression, youth mental wellness, clinical psychology, digital intervention, healthcare technology, telemedicine, behavioral health, acquired, Big Health, Ben Lewis, Jon Sockell, mental health treatment, pediatric mental health

Talent graph

Limbix's talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Limbix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage
Series A 7 investors entered at this stage

Global footprint

Where Limbix has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

What the market is saying about Limbix

An AI-synthesized read of the highest-engagement posts about Limbix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Limbix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.